8-K current report · filed Oct 14, 2026

Verastem, Inc. (VSTM) 8-K Current Report: October 14, 2026

Item 5.02Item 8.01Item EX-99.1Item EX-99.2Item EX-99.3Item 2.02Item 7.01VSTM overview

Short answer

Verastem, Inc. (VSTM) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Preliminary Q3 2026 net product revenue $23.9M-$24.1M, versus $11.2M in Q3 2025.

Verastem, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Preliminary Q3 2026 net product revenue $23.9M-$24.1M, versus $11.2M in Q3 2025
  • Revenue roughly doubled year over year, signaling materially stronger product commercialization
  • Cash, cash equivalents and investments $172.8M at September 30, 2026, versus $137.7M a year earlier
  • Preliminary figures remain unaudited and subject to closing adjustments, limiting near-term certainty

Item 5.02 · Departure/Election of Directors or Officers

  • CEO Daniel W. Paterson retires January 1, 2027, but remains a Class III director through the 2027 annual meeting
  • Michael Bailey, 61, becomes president and CEO January 1, 2027, while continuing as Class II director through 2029
  • Bailey brings commercial oncology experience from AVEO, ImClone, Synta Pharmaceuticals and Genentech
  • CEO compensation and Paterson’s consulting terms remain pending, with disclosure expected in a future 8-K amendment

Item 7.01 · Regulation FD Disclosure

  • CEO transition announcement, signaling a leadership change with potential implications for strategy and execution
  • Initial efficacy data for VS-7375 from the TARGET-D 101 Phase 1/2 trial in advanced KRAS G12D-mutated solid tumors
  • Updated VS-7375 safety and tolerability data, key for assessing clinical-development risk
  • Updated corporate presentation, likely outlining pipeline priorities and development strategy

Item 8.01 · Other Events

  • mPDAC efficacy compelling: 41% confirmed ORR in 2L+, 86% DCR, 67% six-month PFS, and 80% six-month OS
  • NSCLC signals broad activity: 43% confirmed ORR in 2L+ monotherapy and 75% ORR in 1L combination therapy
  • FDA alignment enables first-line mPDAC Phase 3 trial, with opening targeted by year-end 2026
  • Safety supports dose intensity: 2% discontinuation, 97% relative dose intensity, and 10% Grade 3 treatment-related adverse events
  • FDA accepted the NDA for priority review, targeting the first quarter of 2027; ATM terminated with no shares sold under the prospectus

Item EX-99.1 · Exhibit EX-99.1

  • Michael P. Bailey becomes President and CEO January 1, 2027, bringing 30+ years of biopharma experience and 25+ years in oncology
  • Daniel Paterson retires after 35 years in biopharma, remaining an advisor and Verastem director, supporting leadership continuity
  • Strategic priority shifts toward commercial execution for AVMAPKI FAKZYNJA and advancement of VS-7375, an oral KRAS G12D inhibitor
  • VS-7375 has three registration-directed Phase 2 trials underway across pancreatic, lung, and colorectal cancers
  • AVMAPKI FAKZYNJA approval remains accelerated, with continued approval contingent on confirmatory clinical benefit from Phase 3 RAMP 301

Item EX-99.2 · Exhibit EX-99.2

  • VS-7375 showed 50% confirmed ORR in 2L PDAC and 41% in broader 2L+ disease, supporting a potentially differentiated pancreatic cancer profile
  • Two complete responses in 2L+ PDAC, 67% six-month PFS, and 16/22 patients remaining on treatment indicate durable activity
  • FDA alignment on a three-arm first-line PDAC Phase 3 design, with trial opening planned by year-end 2026, materially advances registration strategy
  • 43% confirmed ORR in 2L+ NSCLC and 33% ORR in 3L+ CRC combinations broaden the commercial opportunity beyond pancreatic cancer
  • 900 mg monotherapy showed 2% AE discontinuations, 10% Grade 3 treatment-related events, and 97% median relative dose intensity

Item EX-99.3 · Exhibit EX-99.3

  • VS-7375 shows early efficacy across PDAC, CRC, and NSCLC, supporting Verastem’s strategy to develop a broad KRAS G12D franchise
  • PDAC 900mg monotherapy: 41% confirmed ORR, 67% six-month PFS, and 80% six-month OS in 22 patients
  • NSCLC 600mg monotherapy: 43% confirmed ORR and 72% six-month PFS in 23 previously treated patients
  • Combination signals expand opportunity: 33% ORR in third-line CRC and 75% ORR in first-line NSCLC, both very small cohorts
  • 900mg safety profile supports continued development: 97% dose intensity and 2% discontinuation from treatment-related adverse events

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Verastem, Inc. 8-K filings

Get the next VSTM 8-K as it lands

Follow VSTM for push alerts, or ask the research agent what this filing means.